A star average mixes jobs the label keeps apart
Neurontin is indicated for management of postherpetic neuralgia in adults, and as adjunctive therapy for partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy. A review page that pools shingles pain, seizure add-on treatment, and whatever else people were prescribed will print one average. That average cannot tell you which job improved.
Consumer star averages are not a response rate from a controlled trial. This note uses the labeled trial arms, not marketplace ratings.
The same search also showed a fibromyalgia forum thread, two videos, a Mayo Clinic Connect discussion, and a PubMed title about side effects. The PubMed page returned a cookie wall, so this note does not quote that paper. A forum thread can describe one person's night. It does not add an indication.
Postherpetic neuralgia: two controlled trials
Neurontin was evaluated for postherpetic neuralgia in two randomized, double-blind, placebo-controlled, multicenter studies. The intent-to-treat population was 563 patients with pain for more than 3 months after the herpes zoster rash healed. Study 1 lasted 8 weeks and targeted 3600 mg/day. Study 2 lasted 7 weeks and targeted 1800 or 2400 mg/day. Patients scored pain from 0 to 10 and needed a baseline mean of at least 4 to be randomized. Both studies demonstrated efficacy compared to placebo at all doses tested. Comparable treatment effects were observed in all active treatment arms. That is why the dosing section can say efficacy was shown from 1800 mg/day to 3600 mg/day, and why the additional benefit of using doses greater than 1800 mg/day was not demonstrated. A review that says "the higher capsule worked better" is ahead of those arms.
How people felt on those trials is the part star ratings often describe without the placebo column. In the pooled postherpetic neuralgia trials, dizziness was 28% on Neurontin and 8% on placebo, somnolence was 21% versus 5%, and peripheral edema was 8% versus 2%. Sixteen percent of 336 patients on Neurontin and 9% of 227 on placebo stopped for an adverse reaction. The reactions that most often led to withdrawal were dizziness, somnolence, and nausea. A review that calls the drug too foggy is pointing at the same effects. A review that calls it weightless sedation is not.
Add-on partial seizures, not a solo seizure cure
The effectiveness of Neurontin as adjunctive therapy, added to other antiepileptic drugs, was established in placebo-controlled trials in patients 3 years and older with refractory partial seizures. Three trials included 705 patients age 12 and above. One trial included 247 children ages 3 to 12. People in those studies were still having seizures on their existing drugs. Neurontin or placebo was added. A responder was a patient with a 50% or greater reduction in seizure frequency.
In one adult study of 1200 mg/day in three divided doses, the responder rate was 23% (14 of 61) on Neurontin and 9% (6 of 66) on placebo. That is a real difference in a hard-to-treat group. It is not a promise that most people become seizure-free, and it is not evidence for using gabapentin alone as the only seizure drug. The label's phrase is adjunctive therapy.
In add-on epilepsy trials in patients older than 12, the common effects that outran placebo included somnolence, dizziness, ataxia, fatigue, and nystagmus. About 7% of 2,074 patients in that age group in premarketing trials stopped for an adverse reaction. Pediatric trials also tracked emotional lability, hostility, thought disorder, and hyperkinesia. Those are reasons a parent's review can sound different from an adult pain review. They are still trial columns, not a star.
What to do with a review you just read
Read the job first. If the prescription is postherpetic neuralgia, the controlled comparison is the two trials above, not a 7.1 that also includes other uses. If the prescription is add-on partial seizures, the comparison is seizure frequency on top of the drugs already in use, including that 23% versus 9% responder split in the 1200 mg study. If the review is about a use this label's clinical-studies section does not test, the star does not fill that gap.
Kidney function still changes the milligrams. That table is on the gabapentin 300 mg dosing note. How the capsule got its name, and how promotion ran past the first licence, is on the Neurontin history note. The medicine page is Neurontin. The trial wording was read from the Neurontin label on DailyMed.
Stopping still takes at least a week. Antiepileptic drugs should not be stopped abruptly because seizure frequency can rise. Respiratory depression can occur with other CNS depressants, including opioids. Those warnings sit on the label beside the efficacy sentences. A high star rating does not retire them.
Reviewed against the Neurontin prescribing information on DailyMed on 24 October 2026. The 7.1 and 6.0 figures are search-snippet displays from that day, not trial results.